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Background: Several emerging problems of regular hemodialysis (HD) including cardiovascular complication or 
atherosclerosis formation caused by chronic inflammation. High sensitive C-reactive protein (hs-CRP) and intima-media 
thickness (IMT) of the carotid artery can be applied as atherosclerosis progressivity marker. This study was designed to 
investigate the relationship between some inflammatory factors, including hs-CRP, interleukin (IL)-6, oxidized-low-density 
lipoproteins (LDL), with  IMT  among end-stage renal disease (ESRD) patients. This was the first study in Indonesian 
population. 
Materials and Methods: This cross-sectional study was performed on ESRD patients who performed regular HD at 
Hemodialysis Unit of Dr. Kariadi Hospital and Telogorejo Hospital Semarang between October 2009 and April 2010. This 
was a preliminary report for the cohort study.   
Results: Seventy-eight HD subjects were enrolled in this study, with mean age of 49.8 years old. Mean HD duration was 
25.5±32.16 months. The mean carotid artery wall thickness was 0.64±0.149 mm.  IL-6, hs-CRP, and ox-LDL level were higher 
in IMT group ≥0.5 mm than IMT group <0.5 mm. There was a significant correlation between hs-CRP (prevalence ratio 
(PR)=1.3; 95% confidence interval (CI)=1.02-1.7; p-value=0.01) as well as IL-6 (PR=1.5; 95% CI=1.1 -2.0; p-value<0.001)  and 
IMT wall thickness. The oxidized-LDL level was not a significant factor to be associated with IMT. The cut-off value for hs-
CRP and IL-6 to predict IMT progressivity was 2.8 mg/L and 2.88 mg/L, respectively.
Conclusion: There was a significant correlation between IL-6 and hs-CRP levels and IMT. There was not significant correlation 
between oxidized LDL and IMT.
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Introduction
 As of December 31, 2015, ~0.7 million patients 
were being treated for end-stage renal disease (ESRD) in 
the United States.1 Hemodialysis (HD) might causes new 
problems  such  as  cardiovascular  complications,  as 
the result of chronic inflammation on dialysis.2 Clinical 
manifestation of cardiovascular complication includes 
atherosclerosis, arteriosclerosis and cardiomyopathy. 
Cardiovascular  risk factors  are  traditional  risk  factors 
(TRF), uremic-related risk factors (URFR) and other factors 
related to hemodialysis.3 
 There are three main processes related to inflammation 
and atherosclerosis progression, such as reactive oxygen 
species (ROS), interleukin (IL)-6, and high sensitive 
C-reactive protein (hs-CRP) synthesis, and vascular injury.4,5 
Oxidized-low-density lipoproteins (ox-LDL), one of the 
oxidative stress markers and inflammation biomarkers are 
pro-atherogenic.6,7 Chronic inflammation on HD increase 
lipoprotein phospholipid oxidation in the form of ox-LDL. 
Macrophages catch ox-LDL, thus induce IL-6 synthesis.8 
The processes are chronic persistent and lead to endothelial 
dysfunction.  
 Inflammation exposure in HD is supposedly due to 
the type of atherosclerosis progression.9 It may be defined 
by the intimal-medial thickness (IMT) serial examination. 
Carotid IMT study and endothelial adhesion molecules 
in the foreign general population reported that risk of 
myocardial infarction increased in IMT value >0.82 mm 
(0.82-1.2 mm).10 Mannheim Consensus on carotid IMT 
in 2004, IMT value based on age and cardiovascular risk 
factors, from Framingham risk factors, IMT mean 0.63-0.84 
mm.11,12   IMT normal value in normal population reported on 
Salonen study rates <0.5-0.65 mm in 50 years old age with 
the increased of IMT rates up to 0.008 mm/years.13 Study 
of atherosclerosis risk in the community (ARIC) reported 
in hypertension population, IMT value increase 0.01 mm/
year.14,15 Carotid IMT  and endothelial adhesion molecule 
foreign study reported myocardial infarction risk increased 
on IMT value >0.82 mm (0.82-1.2 mm).16,17 This is the first 
study from Central Java Region, Indonesia. 
Materials and methods
This cross-sectional study was done on the subjects who 
received regular HD on Hemodialysis Unit of Dr. Kariadi 
General Hospital and Telogorejo Hospital Semarang from 
October 2009 to April 2010. The study was approved 
by the Ethical Committee of the Faculty of Medicine, 
Diponegoro University/Dr. Kariadi Hospital (No. 66/EC/
FK/RSDK/2010) and was conducted in accordance with the 
Declaration of Helsinki. All subjects were given information 
regarding this study and signed the informed consent. 
 Blood samples were collected after an 8 hours 
overnight fast. The blood collected before dialysis for 
amount 20 mL and keep into ethylenediaminetetraacetic acid 
(EDTA) tube.  Complete blood count was measured by flow 
cytometry method (Cell-Dyn Saphire, Abbott Diagnostics 
Division, Santa Clara, USA), plasma cholesterol, plasma 
triglyceride, serum calcium, phosphate, and plasma albumin 
was measured by homogenous enzymatic colorimetric assay 
(Dade Behring, Siemens, German).
 IL-6 level was measured using the human IL-6 
immunoassay method (Quantikine® HS Elisa kit, R&D 
Systems, Minneapolis, USA). Plasma levels of hs-CRP were 
measured by the particle-enhanced immunoturbidimetric 
method (TMS, Tokyo Boeki Machinery LTD, Tokyo, 
Japan). Serum creatinine (Cr), uric acid (UA), high density 
lipoprotein (HDL), LDL, lactate dehydrogenase (LDH), 
blood glucose (BG), HbA1C, ox-LDL was measured 
by enzymatic method (TMS, Tokyo Boeki Machinery 
LTD, Tokyo, Japan). Homocystein were measured by 
immunoassay method (IMX immunology analyzer, Ensefal 
Medica Prima, Jakarta, Indonesia). We used laboratory of 
Dr. Kariadi Hospital, Biochemistry Laboratory of Gajah 
Mada and Prodia Clinical Laboratory. IMT was measured 
at carotid arteries by B-mode USG (LOGIQ Ultrasound 
system, GE Healthcare P6, year 2010, type 55011) at 
Department of Radiology, Dr. Kariadi Hospital Semarang. 
Measurement of IMT was done by a Radiologist. Blood 
pressure was classified according to 7th Joint National 
Committee (JNC) on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure.
 Correlation between levels of hs-CRP with IMT were 
analyzed with Chi-Square. Correlation levels of IL-6, ox-
LDL with IMT analyzed with Fisher Exact test. Two-sided 
p≤0.05  was considered as statistically significant. These 
data was analysed used SPSS ver 19 (SPSS Inc., Chicago, 
Illinois, United States. 
Results
Most of the subject has normal glucose, HbA1C and 
cholesterol levels. Most of the subject has low LDH level, 
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>0.5 mm
(n=65)
≤0.05
(n=13)
51.3±9.69 42.0±11.18 0.03
0.7
Male 49 (62.8) 9 (11.5) 
Female 16 (20.5) 4 (5.1) 
0.5
Present 11 (14.1) 2 (2.6) 
Absent 52 (66.6) 11 (14.1) 
0.4
Normal  (< 120/80 mmHg) 6 (7.7) 0 (0.0)
Borderline (120/80 - 139/89 mmHg) 15 (19.2) 2 (2.6)
Hypertension (> 140/90 mmHg) 44 (56.4) 11 (14.1)
134.4±87.93 103.9±24.39 0.4
6.0±1.66 5.4±0.55 0.3
144.0±32.27 143.6±27.57 0.9
124.5±64.51 119.7±46.65 0.9
31.3±10.23 37.0±8.03 0.02
7.9±2.43 8.0±2.10 0.8
5.9±2.11 5.5±1.69 0.7
8.8±0.73 8.6±0.51 0.5
25.9±9.66 25.8±6.98 0.6
HDL (mg/dL), mean±SD
Uric acid (mg/dL), mean±SD
Phosphate (mmol/L), mean±SD
Calcium (mmol/L), mean±SD
Homocysteine (μmol/L), mean±SD
Diabetes history, n (%)
Blood pressure status, n (%)
Blood glucose (mg/dL), mean±SD
HbA1C (%), mean±SD
Total cholesterol (mg/dL), mean±SD
Triglyceride (mg/dL), mean±SD
IMT Catagory
pVariables
Age (year), mean±SD
Sex, n (%)
Table 1. Baseline characteristics of subjects according to IMT category (n=78).
high triglyceride and high homocysteine levels. The subjects 
with IMT >0.5 mm were older than IMT ≤0.5 mm (p=0.03). 
The level of HDL is lower in the subject with thickening of 
carotid artery than no thickening (31. 3 vs. 37.0, p=0.02) 
(Table 1). 
 Table 2 showed that according to the mean of the 
right and left IMT of the study, the majority (83.3%) of the 
subjects have carotid artery wall thickness of more than  0.5 
mm. This indicates a wall thickening of carotid artery has 
been noted in more than 80% of patients with regular HD in 
this study population. 
 Levels of IL-6 are higher in the subjects with IMT 
>0.5 mm than subject with IMT <0.5 mm (10.3 vs. 2.7, 
p=0.001). Levels of ox-LDL are higher in the subjects with 
IMT >0.5 mm than subject with IMT <0.5 mm (102,657.5 
vs. 66,714.4,  p=0.03). Levels of  hs-CRP are higher in the 
subjects with IMT >0.5 mm than subject with IMT <0.5 mm 
(10.1 vs. 3.0,  p=0.003) (Table 3). 
 Table 4 showed the trend of thickening IMT and risk 
of cardiovascular disease according to levels of hs-CRP. 
The trend of thickening carotid artery linear to the risk of 
cardiovascular disease.  The group with IMT 0.5 mm have a 
high risk of cardiovascular disease. This result is significant 
statistically (X2, p=0,004). 
 There is a correlation between hs-CRP levels and 
IMT (prevalence ratio (PR)=1.3; 95% confidence interval 
(CI)=1.02-1.7; p=0.01). Table 5 showed that subject with 
hs-CRP levels >2.8 mg/L have the risk of 1.3 progress 
to thickening of the carotid artery. The sensitivity and 
specificity are 67.7% and  69.2%, respectively. The positive 
predictive value (PPV) is 30.0 % and accuracy 67.9%. There 
are correlation between IL-6 levels and IMT (PR=1.5;  95% 
CI=1.1-2.0; p<0.001). 
 The subject with IL-6 levels >2.9 mg/L has risk 
1.5 times to progress to thickening of the carotid artery. 
The sensitivity and specificity are 73.8% and 76.9%, 
respectively. PPV and negative predictive value (NPV) are 
94.5% and 37.0%, respectively.  There was not significant 
correlation between ox-LDL levels and IMT (PR=1.2; 95% 
CI 0.9-1.6; p=0.1).
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Table 2. Carotid artery IMT examination, by B-mode Doppler ultrasound.
Mean±SD Proportionsn (%)
0.65±0.188 -
0.63±0.150
0.64±0.149
>0.5 mm - 61 (78.2) 
≤0.5 mm - 17 (21.8) 
>0.5 mm - 65 (83.3) 
≤0.5 mm - 13 (16.7) 
Right carotid artery examination
Wall thickness
Right carotid artery (mm)
Left carotid artery  (mm)
Mean carotid artery wall thickness (mm)  
Left carotid artery examination
Note: According to mean carotid artery wall thicknes.
*Mann-Whitney test; SD: standard deviation.
>0.5 mm 
(Mean±SD)
≤0.5 mm 
(Mean±SD)
 IL-6 (pg/mL) 10.3±12.6 2.7±2.16 0.001
 Ox-LDL (ng/mL) 102,657.5±90,844.3 66,714.4±24,866.9 0.03
 hs-CRP (mg/L) 10.1±12.5 3.0±3.5 0.003
IMT
p *Variables
Table 3. Pro-inflammatory factors of the subject according to the IMT. 
Discussion
The majority of subjects in this study have sustained 
carotid IMT thickening. This result was similar to the 
Salonen, reporting that the higher the age, thus the thicker 
the IMT.13 There was a similar study by Kawamoto, et al., 
in Japan, which reported the interaction between IMT and 
subendothelial plaque, and diabetes mellitus with a high 
level of CRP.18 In Kawamoto study, the plaque was included 
on IMT thickness, but in this study, IMT was examined 
in the area that free of plaque. This might give a different 
result on the interaction of diabetes mellitus and IMT on 
both studies.  
 This study showed hs-CRP could be an indicator of 
IMT thickening, and Kawamoto did not analyze this. The 
subjects with thick IMT had the IL-6 level higher than 
subjects with no thick IMT and IL-6 analysis could be 
an indicator of IMT thickness. A cross-sectional study by 
Kato, et al., reported a high level of IL-6 in hemodialysis 
patients who had atherosclerosis compared to the healthy 
subject.19 Subjects with thick IMT majority had ox-LDL 
level higher than non-thick IMT subject, but in this study 
ox-LDL could not be an indicator of IMT. Another study 
also reported the correlation between ox-LDL and anti-ox-
LDL with IMT, neither ox-LDL nor anti-ox-LDL has any 
correlation with cardiovascular mortality in hemodialysis 
population, but there was a correlation between ox-LDL 
and anti-ox-LDL with cardiovascular mortality in general 
population.20 The difference was explained that in chronic, 
there was a considerable hemodialysis-accumulated uremic 
toxin substances that activated ox-LDL and anti-ox-LDL 
formation.  
 Carotid IMT testing is a safe, noninvasive and cost 
effective method to detect early atherosclerotic vascular 
diseases.21 Cardiovascular disease is still the main cause 
of death (50%) in ESRD patients with hemodialysis where 
the non-traditional risk factors (oxidative stress, uremia, 
overload, renin-angiotensin system, uremic toxin, pro-
inflammatory cytokines) play a greater role in changes in 
vascular homeostasis and atherosclerosis.22-24 Changes in 
the structure of the carotid artery can be a window of change 
in the structure of the coronary arteries. The common IMT 
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Table 4. Correlation between the thickening of carotid artery and hs-CRP 
level (n=78). 
>0.5mm
(n=65)
≤0.55
(n=13)
 Low risk (<1 mg/L) 9 (11.5%) 7 (9.0%) 16 (20.5%) 
 Average risk (1-3 mg/L) 13 (16.7%) 2 (2.6%) 15 (19.2%) 
 High risk (>3 mg/L) 43 (55.1%) 4 (5.1%) 47 (60.3%) 
 Total  13 (16.7%) 78 (100%) 
Level of hs-CRP 
IMT Category
Total
X2 test; p=0.004; According to AHA/CDC recommendation.
>0.5 mm
(n=65)
≤0.5 mm
(n=13)
Levels of hs-CRD  0.01a 1.3 (1.02-1.7)
 >2.8 (mg/L) 44 (56.4%) 4 (5.1%) 
 ≤2.8 (mg/L) 21 (26.9%) 9 (11.5%) 
Levels of IL-6  <0.001b 1.5 (1.1 -2.0)
 >2.9 (pg/mL) 48 (61.5%) 3 (3.8%) 
 ≤2.9 (pg/mL) 17 (21.8%) 10 (12.8%) 
0.1b 1.2 (0.9-1.6)
 >73.75 (ng/mL) 47 (60.3%) 6 (7.7%)
 ≤73.75 (ng/mL) 18 (23.1%) 7 (9.0%)
Prevalence 
Ratio 
(95% CI)
Levels of ox-LDL  
IMT category
p
aChi-square test; bFisher exact test; The cut-off value of hs-CRP, IL-6, ox-LDL were 2.8, 
2.9, 74.5 respectively. These value were calculated by ROC.
Table 5. Correlation between the levels of hs-CRP, IL-6, ox-LDL with IMT thickness 
(n=78).
examination was correlated with coronary atherosclerosis.25 
Early identification of IMT must be done in order to prevent 
increased morbidity and mortality of cardiovascular disease 
or atherosclerosis progression. 
 Vascular complications in the HD subjects of is mainly 
driven by inflammatory factors and overexpression of 
oxidative stress-that activated by exposure to hemodialysis 
and the effects of uremia. This vascular damage is influenced 
by advanced glycation end product (AGE-s) which 
accumulates in the serum and tissue of ESRD hemodialysis 
patients. High levels of AGE-s in the ESRD patients with 
hemodialysis are not affected by diabetes or non-diabetic 
status.26,27
 Szeto, et al., reported in the Chinese population also 
reported the same result with a lower incidence rate of 
carotid artery IMT thickness (59.6 %).13 This difference 
in incidence is probably due to differences in the degree 
of CKD in the research subjects used. In this study, the 
research  subjects  were  ESRD  patients  while  in  Szeto's 
study the subjects of the study were CKD patient with stage 
3 and 4.13 
Conclusion
There is a correlation between IL-6 and hs-CRP and IMT, 
thus it can be used as an indicator of IMT on ESRD-regular 
HD. There is not significant correlation between oxidized 
LDL and IMT.  
 The hs-CRP level can be examined periodically on 
ESRD patients to detect early atherosclerosis complications 
in Hemodialysis Unit, also to improve the life expectancy 
of ESRD patients. Further studies should be done to follow 
up the progressive IMT on regular hemodialysis ESRD 
patients and to prevent progressive IMT.
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